



Vivimed

Dated : August 14,2012

To
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

Dear Sir/Madam,

Subject : Outcome of Board Meeting

Ref: Clause 41 of Listing Agreement

With reference to captioned subject and pursuant to clause 41 of Listing Agreement entered into with the stock Exchange, we are hereby submitting Unaudited financial results for the Quarter ended on June 30,2012 approved by the Board of Directors at their meeting held on August 13,2012.

This is for your information and records.

Thanking You,

For VIVIMED LABS LIMITED

Subhash Varalwar

Whole Time Director

VIVIMED LABS LIMITED

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th, 2012

(INR in Lacs)

Sl. No.	Particulars	3 Months ended 30-06-2012 (Q1FY13) (Unaudited)	Preceding 3 Months ended 31-03-2012 (Q4FY12) (Unaudited)	Corresponding 3 Months ended 30-06-2011 (Q1FY12) (Unaudited)	Previous Year ended 31-03-2012 (FY12) (Audited)
1	Income From Operations				
	(a) Net Sales / Income from Operations (Net of Excise Duty)	9,116.06	9,110.58	10,392.96	38,289.99
	(b) Other Operating Income	38.93	16.07	2.00	41.96
	Total Income From Operations (Net)	9,154.99	9,126.64	10,394.97	38,331.95
2	Expenses	7,204.08	7,248.56	8,457.94	30,944.43
	a. Cost of Raw Materials Consumed	6,475.81	4,752.53	6,106.81	22,930.02
	b. Purchase of Stock in Trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,028.62)	671.40	(66.04)	(156.78)
	d. Employee Benefit Expenses	341.75	234.79	288.18	1,057.86
	e. Depreciation and Amortisation Expenses	372.43	456.17	141.22	1,055.10
	f. Other Expenditure	2,042.71	1,133.66	1,987.77	6,058.23
	Total Expenses	7,204.08	7,248.56	8,457.94	30,944.43
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	1,950.91	1,878.09	1,937.03	7,387.52
4	Other Income	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	1,950.91	1,878.09	1,937.03	7,387.52
6	Finance Costs	895.01	450.48	586.55	2,253.49

Dhan

7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,055.90	1,427.61	1,350.48	5,134.02
8	Exceptional items	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	1,055.90	1,427.61	1,350.48	5,134.02
10	Tax Expenses	211.18	350.99	270.20	1,092.57
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	844.72	1,076.61	1,080.28	4,041.46
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	844.72	1,076.61	1,080.28	4,041.46
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	844.72	1,076.61	1,080.28	4,041.46
17	Paid up Equity Share Capital (Face value of Rs.10/- each)	1393.39	1393.39	1,016.40	1,393.39
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	25,672.32	-	25,672.32
19	Earnings per Share (before Extraordinary Items) (of Rs. 10/- each) (not annualised)	-	-	-	-
	(a) Basic	6.06	7.73	10.63	29.00
	(b) Diluted	5.26	6.70	8.93	25.16

1. The above Standalone Unaudited Financial Results for the Quarter ended June 30th June , 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on August 13, 2012.

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED



(SUBHASH VARALWAR)

Whole Time Director

Place : Hyderabad

Date : 13 / 08 / 2012

VIVIMED LABS LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th' 2012

Sl. No.	Particulars	3 Months ended	Preceding	Corresponding	(INR in Lacs)
		30-06-2012 (Q1FY13) (Unaudited)	3 Months ended 31-03-2012 (Q4FY12) (Unaudited)	3 Months ended 30-06-2011 (Q1FY12) (Unaudited)	ended 31-03-2012 (FY12) (Audited)
1	Income From Operations				
	(a) Net Sales / Income from Operations (Net of Excise Duty)	27,251.66	25,106.01	12,054.11	66,831.38
	(b) Other Operating Income	180.85	90.03	8.32	268.23
	Total Income From Operations (Net)	27,432.52	25,196.03	12,062.43	67,099.61
2	Expenses				
	a. Cost of Raw Materials Consumed	13,969.45	11,525.30	7,019.17	56,480.55
	b. Purchase of Stock in Trade	-	-	-	35,573.68
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	(2,974.65)	202.11	(662.34)	(1,835.31)
	d. Employee Benefit Expenses	1,424.33	1,387.86	486.45	3,422.45
	e. Depreciation and Amortisation Expenses	1,413.00	1,345.77	264.60	2,678.94
	f. Other Expenditure	8,819.42	7,362.96	2,748.22	16,640.79
	Total Expenses	22,651.54	21,824.00	9,856.10	56,480.55
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	4,780.97	3,372.04	2,206.33	10,619.06
4	Other Income	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	4,780.97	3,372.04	2,206.33	10,619.06
6	Finance Costs	1,589.06	809.90	650.65	2,837.54
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	3,191.92	2,562.13	1,555.68	7,781.52
8	Exceptional items	-	-	-	-

Chun

9	Profit / Loss from ordinary activities before Tax (7 - 8)	3,191.92	2,562.13	1,555.68	7,781.52
10	Tax Expenses	578.94	332.54	316.42	1,467.84
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,612.98	2,229.59	1,239.26	6,313.68
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	2,612.98	2,229.59	1,239.26	6,313.68
14	Share of Profit / (Loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,612.98	2,229.59	1,239.26	6,313.68
17	Paid up Equity Share Capital (Face value of Rs.10/- each)	1,393.39	1,393.39	1,016.40	1,393.39
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-
19	Earnings per Share (before Extraordinary Items)(of Rs.10/- each)(not annualised)	-	-	-	-
	(a) Basic	18.75	16.00	12.19	45.31
	(b) Diluted	16.26	13.88	10.24	39.31

- The above Consolidated Unaudited Financial Results for the Quarter ended June 30, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on August 13, 2012.
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited and its step down subsidiaries viz. (i) Vivimed Labs Europe Limited (ii) Vivimed Labs Mauritius Limited (iii) Vivimed Labs UK Limited, (iv) Vivimed Labs Spain, S.L. (v) Union Quimico Farmaceutica S.A., Spain, (vi) Uquifa Mexico S.A. de C.V. & (vii) Holiday International Limited, UK.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED



(SUBHASH VARALWAR)

Whole Time Director

Place : Hyderabad
Date : 13 / 08 / 2012

Part II					
Select Information for the Quarter Ended 30/06/2012					
	Particulars	3 months ended 30/06/2012	Preceding 3 months ended 31/03/2012	Corresponding 3 months ended 30/06/2011 in the previous year	Previous Year ended 31/03/2012
A	PARTICULARS OF SHAREHOLDING				
	Public shareholding				
	Number of Shares	76,41,739	76,42,476	50,98,643	76,42,476
	Percentage of Shareholding	54.84	54.85	50.16	54.85
	Promoter and Promoter Group Shareholding				
	(a) Pledged/ Encumbered				
	Number of Shares	12,52,455	10,52,455	10,52,455	10,52,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.90	16.73	20.78	16.73
	Percentage of shares (as a % of the total share capital of the company)	8.99	7.55	10.35	7.55
	(b) Non -encumbered				
	Number of Shares	50,39,748	52,39,011	40,12,918	52,39,011
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	80.10	83.27	79.22	83.27
	Percentage of shares (as a % of the total share capital of the company)	36.17	37.60	39.49	37.60

	Particulars	3 months ended 30/06/2012
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Oman

VIVIMED LABS LIMITED - STANDALONE
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT

(INR in lacs)

Particulars	3 Months ended		3 Months ended		12 Months ended
	Unaudited		Unaudited		Audited
	30.06.12	30.06.11	30.06.12	30.06.11	31.03.2012
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	6,848.02	7,644.10	6,848.02	7,644.10	27,905.80
b.Pharma Business	2,268.04	2,748.85	2,268.04	2,748.85	10,426.14
Total	9,116.06	10,392.95	9,116.06	10,392.95	38,331.94
Less, Inter Segment Revenue					
Net sales / Income from Operations	9,116.06	10,392.95	9,116.06	10,392.95	38,331.94
2.Segment Results (Profit) (+) / Loss (-)before tax and interest from each segment					
a.Speciality Chemicals Business	1,524.61	1,374.33	1,524.61	1,374.33	4,970.17
b.Pharma Business	426.30	562.70	426.30	562.70	2,417.35
Total	1,950.91	1,937.03	1,950.91	1,937.03	7,387.52
Less: 1.Interest 2.OtherUn-allocable Expenditure net off	895.01	586.50	895.01	586.50	2,253.49
3.Un-allocable Income					
Total Profit Before Tax	1,055.90	1,350.48	1,055.90	1,350.48	5,134.02
3. Capital Employed (Segment Assets - Segment Liabilities)					
a.Speciality Chemicals Business	72,547.15	34,957.10	51,365.15	34,957.10	64,436.00
b.Pharma Business	7,264.00	4,134.70	6,394.00	4,134.70	6,003.20
Total	79,811.15	39,091.80	57,759.15	39,091.80	70,439.20

Chman


VIVIMED LABS LIMITED - CONSOLIDATED
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT

(INR in Lacs)

Particulars	3 Months ended		3 Months ended		12 Months
	Unaudited		Unaudited		Audited
	30.06.12	30.06.11	30.06.12	30.06.11	31.03.12
1. Segment Revenue (Net Sales/Income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	10,516.66	10,251.74	10,516.66	10,251.74	41,864.76
b. Pharma Business	19,084.10	3,778.53	19,084.10	3,778.53	33,205.11
Total	29,600.76	14,030.27	29,600.76	14,030.27	75,069.87
Less : Inter Segment Revenue	2,349.09	1,976.16	2,349.09	1,976.16	8,238.49
Net sales / Income from Operations	27,251.66	12,054.11	27,251.66	12,054.11	66,831.38
2. Segment Results(Profit)(+)/Loss(-) before tax and interest from each segment					
a. Speciality Chemicals Business	1,969.79	1,504.19	1,969.79	1,504.19	6,006.96
b. Pharma Business	2,811.19	702.14	2,811.19	702.14	4,612.10
Total	4,780.98	2,206.33	4,780.98	2,206.33	10,619.06
Less: 1. Interest	1,589.06	650.65	1,589.06	650.65	2,837.54
2. Other Un-allocable Expenditure net off	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
Total Profit Before Tax	3,191.92	1,555.68	3,191.92	1,555.68	7,781.52
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Speciality Chemicals Business	76,345.97	49,530.42	73,722.17	49,530.42	68,234.97
b. Pharma Business	43,094.25	6,789.12	43,555.23	6,789.12	40,330.25
Total	1,19,440.22	56,319.54	1,17,277.41	56,319.54	1,08,565.22

For Vivimed Labs Limited

Place : Hyderabad
Date : 13 / 08 / 2012


(SUBHASH VARALWAR)
 Whole Time Director